Related Experiment Videos
[Visceral leishmaniasis: new drugs]
P Minodier1, S Robert, K Retornaz
1Urgences pédiatriques, CHU Nord, chemin des Bourrelly, 13915 Marseille 20, France. philippe.minodier@ap-hm.fr
Summary
Pentavalent antimony is the standard treatment for visceral leishmaniasis but is becoming less effective and more toxic. Liposomal amphotericin B (Ambisome) offers a safer, effective alternative, with shorter treatment durations showing promise for cost reduction.
Area of Science:
- Infectious Diseases
- Pharmacology
- Tropical Medicine
Background:
- Standard visceral leishmaniasis treatment, pentavalent antimony, faces challenges due to frequent toxicity and increasing drug resistance in immunocompetent and immunosuppressed patients.
- Amphotericin B, a potent antileishmanial agent, exhibits toxicity that can be mitigated through lipid-based formulations.
- Liposomal amphotericin B (Ambisome) presents a potentially safer alternative to conventional amphotericin B formulations.
Purpose of the Study:
- To evaluate the efficacy and safety of liposomal amphotericin B (Ambisome) as a treatment for visceral leishmaniasis.
- To determine optimal drug regimens for Ambisome, considering geographical variations.
- To explore strategies for reducing the cost of Ambisome therapy, such as shortening treatment duration.
Main Methods:
- Review of existing literature on visceral leishmaniasis treatments.
- Analysis of clinical data on the efficacy and toxicity of pentavalent antimony and amphotericin B formulations.
- Evaluation of liposomal amphotericin B (Ambisome) treatment regimens in the Mediterranean Basin.
Main Results:
- Liposomal amphotericin B (Ambisome) demonstrates significant antileishmanial activity with potentially reduced toxicity compared to other amphotericin B formulations.
- A total Ambisome dose of 18 to 24 mg/kg is identified as safe and effective in the Mediterranean Basin.
- Shortening Ambisome treatment duration to 10 mg/kg/day for 2 days, without altering the total dose, is a promising approach to reduce therapy costs.
Conclusions:
- Liposomal amphotericin B (Ambisome) is a highly effective and safer alternative for visceral leishmaniasis treatment compared to standard pentavalent antimony.
- Optimized Ambisome regimens, including shorter treatment durations, can improve patient outcomes and reduce healthcare costs.
- Further research into cost-effective Ambisome dosing strategies is warranted to enhance accessibility in endemic regions.